The Potential Dangers of Using MDMA for Psychotherapy
This review (2014) examines both the negative and positive aspects of using MDMA for psychotherapy, with specific regard to its neurohormonal profile, the effects of serotonergic depletion, and neurotoxicity of repeated usage. The most critical issues are related to the release of difficult feelings and memories and the lack of control thereof due to heightened environmental sensitivity, as well as the risk that negative mood states predominating the phase of neurochemical recovery amongst certain individuals.
Authors
- Parrott, A. C.
Published
Abstract
Introduction
MDMA has properties that may make it attractive for psychotherapy, although many of its effects are potentially problematic. These contrasting effects will be critically reviewed in order to assess whether MDMA could be safe for clinical usage. Early studies from the 1980s noted that MDMA was an entactogen, engendering feelings of love and warmth. However, negative experiences can also occur with MDMA since it is not selective in the thoughts or emotions it releases. This unpredictability in the psychological material released is similar to another serotonergic drug, LSD. Acute MDMA has powerful neurohormonal effects, increasing cortisol, oxytocin, testosterone, and other hormone levels. The release of oxytocin may facilitate psychotherapy, whereas cortisol may increase stress and be counterproductive. MDMA administration is followed by a period of neurochemical recovery, when low serotonin levels are often accompanied by lethargy and depression. Regular usage can also lead to serotonergic neurotoxicity, memory problems, and other psychobiological problems.
Discussion
Proponents of MDMA-assisted therapy state that it should only be used for reactive disorders (such as PTSD) since it can exacerbate distress in those with a prior psychiatric history. Overall, many issues need to be considered when debating the relative benefits and dangers of using MDMA for psychotherapy.
Research Summary of 'The Potential Dangers of Using MDMA for Psychotherapy'
Introduction
The paper opens with a historical overview of MDMA's emergence as an agent considered for psychotherapy. Parrott recounts Alexander Shulgin's early reports that MDMA produced ‘‘entactogenic’’ effects—feelings of warmth, love and increased emotional openness—and how informal therapeutic uses in the 1970s–1980s prompted interest in MDMA as a drug adjunct. At the same time, recreational use expanded and, after legal prohibition in 1986, a growing empirical literature documented both positive subjective effects and a range of adverse outcomes associated with repeated use. Against this background, the paper sets out to critically review contrasting lines of evidence on MDMA’s acute psychological and neurohormonal effects, the post-use recovery period, and longer-term psychobiological consequences. Parrott aims to assess whether MDMA could plausibly be safe for clinical use in psychotherapy, emphasising questions about unpredictability of emergent material, neurochemical after-effects, possible neurotoxicity and psychiatric vulnerability in recipients.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typemeta
- Journal
- Compound
- Topics
- APA Citation
Parrott, A. C. (2014). The Potential Dangers of Using MDMA for Psychotherapy. Journal of Psychoactive Drugs, 46(1), 37-43. https://doi.org/10.1080/02791072.2014.873690
References (2)
Papers cited by this study that are also in Blossom
Greer, G. R. · Journal of Psychoactive Drugs (1986)
Liechti, M. E., Gamma, A., Vollenweider, F. X. · Psychopharmacology (2001)
Cited By (12)
Papers in Blossom that reference this study
Morgan, L. · Annals of General Psychiatry (2020)
Schmid, Y., Gasser, P., Oehen, P. et al. · Journal of Psychopharmacology (2020)
Krediet, E., Bostoen, T., Breeksema, J. J. et al. · International Journal of Neuropsychopharmacology (2020)
Berquist, M. D., Leth-Petersen, S., Kristensen, J. L. et al. · Drug and Alcohol Dependence (2020)
Reiff, C. M., Richman, E. E., Nemeroff, C. B. et al. · American Journal of Psychiatry (2020)
Jungaberle, H., Thal, S., Zeuch, A. et al. · Neuropharmacology (2018)
Szigeti, B., Winstock, A. R., Erritzoe, D. et al. · Journal of Psychopharmacology (2018)
Fattore, L., Piva, A., Zanda, M. T. et al. · Psychopharmacology (2017)
Vizeli, P., Liechti, M. E. · Journal of Psychopharmacology (2017)
Aarde, S. M., Taffe, M. A. · Neuropharmacology (2016)
Show all 12 papersShow fewer
Danforth, A. L., Struble, C., Yazar-Klosinski, B. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)
Mueller, F., Lenz, C., Steiner, M. et al. · Neuroscience and Biobehavioral Reviews (2015)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.